Gefitinib
Signals from filings dated January 2026 – January 2026 · Last checked 7 Nov 2026
Supply outlook
↓ SHRINKINGIn the filings we track: 0 plants adding this molecule, 1 exit signal, 0 intermediate projects.
Signals
Fusion Health Care Pvt. Ltd.
Sy. No. 667, Bhiknoor, Kamareddy, Telangana
- ✓ Terms of reference
- ✓ Public hearing · 7 Jan 2026
- Next: clearance
- Consent to operate
- DMF / CEP
Filed as genfitinib (sic). Capacity 166.67 → 150 kg/day (-16.67). Expansion of an approved API unit still under construction (EC 2021; taken over by Fusion Health Care in 2023). Worst case 6 products run at once; site total 1,000 to 2,420 kg/day. Public hearing held 7 Jan 2026. Source: EIA executive summary, TGPCB
Who makes Gefitinib today: 108 listings
Current manufacturers with US DMF and CEP status, plant addresses and contacts.
| Manufacturer | Country | US DMF | CEP | Contact |
|---|---|---|---|---|
| Tecoland Corp. | United States | ✓ | — | In database |
| Khandelwal Laboratories | India | — | — | In database |
| Shanghai TKing Chemical Co., Ltd. | China | — | — | In database |
| + 105 more listings in api-fdf.com → | ||||
Three examples from the api-fdf.com database, refreshed weekly. Plant addresses and contacts are shown in the database.
Follow Gefitinib
Get an email when a new filing adds, cuts or moves this molecule to the next stage.